Exenatide Use in the Management of Type 2 Diabetes Mellitus

Exenatide Use in the Management of Type 2 Diabetes Mellitus

Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin sec...

Full description

Bibliographic Details
Main Authors:	Angelos Kyriacou, Abu Baker Ahmed
Format:	Article
Language:	English
Published:	MDPI AG 2010-08-01
Series:	Pharmaceuticals
Subjects:	diabetes exenatide glycaemic control incretin mimetics efficacy adverse events
Online Access:	http://www.mdpi.com/1424-8247/3/8/2554/

Similar Items

New indications for exenatide therapy of type 2 diabetes mellitus
by: Olga Konstantinovna Vikulova, et al.
Published: (2010-09-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01)

CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01)

Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
by: Chuanmin Bai, et al.
Published: (2022-09-01)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016-07-01)

Exenatide for obesity in children and adolescents: Systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2024-04-01)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
by: Alina Babenko, et al.
Published: (2014-12-01)

The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis
by: Davut Sakız, et al.
Published: (2022-07-01)

Association between exenatide use and incidence of Alzheimer's disease
by: Bo Zhou, et al.
Published: (2021-01-01)

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
by: Jinfang Song, et al.
Published: (2022-08-01)

The first successful desensitization protocol in exenatide allergy: a case report
by: Osman Ozan Yeğit, et al.
Published: (2023-01-01)

Triple therapy for obese patients with type 2 diabetes: evaluating effectiveness of the metformin + exenatide + glibenclamide combination
by: M. B. Antsiferov, et al.
Published: (2015-12-01)

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
by: Cobble Michael
Published: (2012-03-01)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
by: João C. Ribeiro, et al.
Published: (2022-05-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment
by: Han Liu, et al.
Published: (2022-06-01)

Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide
by: Yuxuan Ge, et al.
Published: (2021-05-01)

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice
by: Xiaoyan Bao, et al.
Published: (2020-04-01)

What are the consequences of over and undertreatment of type 2 diabetes mellitus in a frail population? A systematic review
by: Helen O'Neil, et al.
Published: (2024-03-01)

Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
by: Xiaojie Jiang, et al.
Published: (2023-12-01)

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION
by: A. Yu. BABENKO, et al.
Published: (2016-12-01)

Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
by: Muhammad Mustafa Abeer, et al.
Published: (2019-08-01)

Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial
by: Xubin Yang, et al.
Published: (2024-01-01)

Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats
by: Jian-Miao Yang, et al.
Published: (2022-05-01)

SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease
by: Mei-jun Wang, et al.
Published: (2023-11-01)

The Effects of pH and Excipients on Exenatide Stability in Solution
by: Alexander Benet, et al.
Published: (2021-08-01)

Metabolic control and depression in type 1 diabetes mellitus
by: Tatiana Vyacheslavovna Mokhort, et al.
Published: (2015-06-01)

Glycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure
by: Edouard Gerbaud, et al.
Published: (2022-03-01)

Ion- and osmoregulating renal functions in patients with type 2 diabetes mellitus
by: Evgeniya Vladimirovna Balbotkina, et al.
Published: (2016-01-01)

Hypoglycaemic treatment adherence and the association with psychological, self‐management and glycaemic characteristics in adults with type 1 diabetes
by: Pamela Martyn‐Nemeth, et al.
Published: (2019-07-01)

Pulmonary tuberculosis and diabetes mellitus: Clinical profile and outcomes
by: John Titus George, et al.
Published: (2022-01-01)

Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study
by: Irene Santos-Pardo, et al.
Published: (2023-12-01)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
by: Sity Aishah Mansur, et al.
Published: (2019-02-01)

Two‐year trends from the LANDMARC study: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcome in patients with type 2 diabetes mellitus
by: Ashok K. Das, et al.
Published: (2023-03-01)

Study on the association of Vitamin D with glycaemic control in patients with type 2 diabetes mellitus
by: P Santosh Kumar, et al.
Published: (2019-01-01)

Soy Flour-Based Snack Bar as Potential Snack Alternative for Diabetes Mellitus
by: Naufal Muharam Nurdin, et al.
Published: (2020-11-01)

A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
by: A. S. Pogorelova
Published: (2018-07-01)

Ileal transposition in surgical treatment for type 2 diabetes mellitus
by: Oleg Viktorovich Kornyushin, et al.
Published: (2015-03-01)

Hypomagnesemia and poor glycemic control among type 2 diabetic patients: A cross-sectional study
by: Mohammad Hamarshih, et al.
Published: (2022-01-01)